TGFB1 and Hepatic fibrosis: N-butyl-fluoperazine iodide inhibits TGF-βR II, reducing the response of HSCs to TGF-β1, decreasing TGF-β/Smad signaling transduction and fibrotic gene expression, improving CCl4- or thioacetamide-induced liver fibrosis in mice in a dose-dependent manner, and alleviating liver function damage and tissue lesions (87).